Real World Evidence Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) - Global Forecast to 2023

リアルワールドエビデンスソリューションの世界市場予測(~2023年)

◆タイトル:Real World Evidence Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) - Global Forecast to 2023
◆商品コード:HIT6444
◆調査・発行会社:MarketsandMarkets
◆発行日:2018年7月10日
◆ページ数:158
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:ヘルスケアIT
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、リアルワールドエビデンスソリューションの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、コンポーネント別(データセット、サービス)分析、治療領域別(腫瘍、心臓血管、免疫)分析、エンドユーザー別(医薬品、医療機器、支払人、医療提供者)分析、リアルワールドエビデンスソリューションの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“The global real world evidence market projected to grow at a CAGR of 14.3%.”The global real-world evidence market is projected to reach USD 1,348.1 million by 2023 from USD 689.9 million in 2018, at a CAGR of 14.3% during the forecast period. The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs). However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection are restraining the growth of this market.

“The services segment is expected to register the highest CAGR during the forecast period.”
On the basis of component, the real world evidence market is segmented into data sets and services. The services segment is expected to register the highest CAGR during the forecast period. The high growth rate of this segment is mainly due to the rising need to convert data into actionable evidence, growing need to reduce drug development delays, and availability of large amounts of healthcare data are the major factors driving market growth in this segment.

“Pharmaceutical & medical device companies segment expected to grow at the highest CAGR during 2018 to 2023.”
Based on end user, the real-world evidence (RWE) market is broadly segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users (academic institutions, patient advocacy groups, and health technology assessment agencies). The pharmaceutical & biopharmaceutical companies segment is the fastest-growing segment in the real world evidence market during the forecast period. The rising demand to assess comparative effectiveness of drugs in actual, real-world use and the value or economic impact from the use of new or existing drugs are the major factors driving the growth of the real world evidence market for pharmaceutical & medical device companies.

“APAC is projected to witness the highest growth during the forecast period.”
North America held the largest share of the global real world evidence market in 2017. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, due to the increasing government initiatives for the adoption of RWE studies, rising burden of chronic diseases, increasing demand for better healthcare services, and the rising geriatric population in the Asia Pacific region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–25%, Tier 2–50% and Tier 3–25%
• By Designation – C-level–25%, Director Level–37%, Others–38%
• By Region – North America–25%, Europe–25%, Asia Pacific–37%, Rest of World–13%

The prominent players in the global real world evidence market are IQVIA (US), International Business Machines Corporation (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).
Research Coverage:
The report analyzes the various real world evidence and their adoption pattern. It aims at estimating the market size and future growth potential of the global real world evidence market for different segments such as by component, therapeutic area, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening the market.

This report provides insights on the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global real world evidence market. The report analyzes the global real world evidence market by component, therapeutic area, end user, and region
• Service Development/Innovation: Detailed insights on upcoming trends and service launches in the global real world evidence market
• Market Development: Comprehensive information on the lucrative emerging regions by component, therapeutic area, end user, and region
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the global real world evidence market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and services of leading players in the global real world evidence market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 17
1.4 YEARS CONSIDERED FOR THE STUDY 18
1.5 LIMITATIONS 18
1.6 CURRENCY 18
1.7 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH APPROACH 20
2.1.1 SECONDARY DATA 22
2.1.1.1 Key data from secondary sources 22
2.1.2 PRIMARY DATA 22
2.1.2.1 Key data from primary source 22
2.1.2.2 Breakdown of primary interviews 23
2.1.2.3 Key industry insights 23
2.2 MARKET SIZE ESTIMATION 24
2.2.1 BOTTOM-UP APPROACH 24
2.2.2 TOP-DOWN APPROACH 25
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 26
2.4 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 31
4.1 REAL-WORLD EVIDENCE: MARKET OVERVIEW 31
4.2 EUROPE REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA AND COUNTRY 32
4.3 REAL-WORLD EVIDENCE MARKET: GEOGRAPHIC SNAPSHOT 33
4.4 REAL-WORLD EVIDENCE: GEOGRAPHIC MIX 34

5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Rising geriatric population and the subsequent increase in the prevalence of chronic diseases 36
5.2.1.2 Shift from volume- to value-based care 37
5.2.1.3 Delays in drug development and the subsequent increase in development costs 37
5.2.2 RESTRAINTS 38
5.2.2.1 Reluctance to rely on real-world studies 38
5.2.3 OPPORTUNITIES 38
5.2.3.1 Growth opportunities in emerging markets 38
5.2.3.2 Rising focus on end-to-end RWE services 39
5.2.4 CHALLENGES 39
5.2.4.1 Lack of universally accepted methodological standards and data processing infrastructure 39
6 INDUSTRY TRENDS 41
6.1 INDUSTRY TRENDS 41
6.1.1 EMERGING ROLE OF WEARABLE DEVICES 41
6.1.2 SOCIAL MEDIA SOURCED REAL-WORLD EVIDENCE 42
6.1.3 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN REAL-WORLD DATA MANAGEMENT 42
6.2 REAL-WORLD DATA SOURCES 43
7 REAL-WORLD EVIDENCE MARKET, BY COMPONENT 45
7.1 INTRODUCTION 46
7.2 DATA SETS 47
7.2.1 CLINICAL SETTINGS DATA 48
7.2.2 CLAIMS DATA 50
7.2.3 PHARMACY DATA 51
7.2.4 PATIENT-POWERED DATA 52
7.3 SERVICES 53
8 REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA 55
8.1 INTRODUCTION 56
8.2 ONCOLOGY 57
8.3 CARDIOVASCULAR DISEASE 58
8.4 NEUROLOGY 59
8.5 IMMUNOLOGY 60
8.6 OTHER THERAPEUTIC AREAS 61
9 REAL-WORLD EVIDENCE MARKET, BY END USER 63
9.1 INTRODUCTION 64
9.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES 65
9.3 HEALTHCARE PAYERS 66
9.4 HEALTHCARE PROVIDERS 67
9.5 OTHER END USERS 68
10 REAL-WORLD EVIDENCE MARKET, BY REGION 70
10.1 INTRODUCTION 71
10.2 NORTH AMERICA 72
10.2.1 US 76
10.2.2 CANADA 78
10.3 EUROPE 81
10.3.1 GERMANY 85
10.3.2 UK 87
10.3.3 FRANCE 89
10.3.4 ITALY 92
10.3.5 SPAIN 94
10.3.6 REST OF EUROPE 97
10.4 ASIA PACIFIC 99
10.4.1 JAPAN 100
10.4.2 CHINA 103
10.4.3 REST OF APAC 106
10.5 REST OF THE WORLD 108
11 COMPETITIVE LANDSCAPE 111
11.1 OVERVIEW 111
11.2 COMPETITIVE SCENARIO 112
11.2.1 MERGERS & ACQUISITIONS 112
11.2.2 PARTNERSHIPS, AGREEMENTS, ALLIANCES, AND COLLABORATIONS 113
11.2.3 SERVICES LAUNCHES 114
12 COMPANY PROFILES 115
(Business overview, Services offered, Recent Developments, SWOT analysis, MNM view)*
12.1 IQVIA 115
12.2 IBM 119
12.3 PHARMACEUTICAL PRODUCT DEVELOPMENT 122
12.4 PAREXEL 125
12.5 OPTUM (A SUBSIDIARY OF UNITED HEALTH GROUP, INC.) 128
12.6 PERKINELMER 132
12.7 ICON PLC 134
12.8 ORACLE 137
12.9 COGNIZANT 139
12.10 SYNEOS HEALTH 141
12.11 ANTHEM 143
12.12 CLINIGEN 146
12.13 SAS INSTITUTE 148
*Details on Business overview, Services offered, Recent Developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.
13 APPENDIX 150
13.1 INSIGHTS OF INDUSTRY EXPERTS 150
13.2 DISCUSSION GUIDE 151
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 154
13.4 AVAILABLE CUSTOMIZATIONS 156
13.5 RELATED REPORTS 156
13.6 AUTHOR DETAILS 157

LIST OF TABLES

TABLE 1 STANDARD CURRENCY CONVERSION RATES 19
TABLE 2 DRIVERS: IMPACT ANALYSIS 37
TABLE 3 RESTRAINTS: IMPACT ANALYSIS 38
TABLE 4 OPPORTUNITIES: IMPACT ANALYSIS 39
TABLE 5 CHALLENGES: IMPACT ANALYSIS 40
TABLE 6 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES 43
TABLE 7 REAL-WORLD EVIDENCE MARKET, BY COMPONENT, 2016–2023 (USD MILLION) 46
TABLE 8 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 47
TABLE 9 REAL-WORLD EVIDENCE DATA SETS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 48
TABLE 10 REAL-WORLD EVIDENCE CLINICAL SETTINGS DATA MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 49
TABLE 11 REAL-WORLD EVIDENCE CLAIMS DATA MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 50
TABLE 12 REAL-WORLD EVIDENCE PHARMACY DATA MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 52
TABLE 13 REAL-WORLD EVIDENCE PATIENT-POWERED DATA MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 53
TABLE 14 REAL-WORLD EVIDENCE SERVICES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 54
TABLE 15 REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 57
TABLE 16 REAL-WORLD EVIDENCE MARKET FOR ONCOLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 58
TABLE 17 REAL-WORLD EVIDENCE MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2016–2023 (USD MILLION) 59
TABLE 18 REAL-WORLD EVIDENCE MARKET FOR NEUROLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 60
TABLE 19 REAL-WORLD EVIDENCE MARKET FOR IMMUNOLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 61
TABLE 20 REAL-WORLD EVIDENCE MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2016–2023 (USD MILLION) 62
TABLE 21 REAL-WORLD EVIDENCE MARKET, BY END USER, 2016–2023 (USD MILLION) 64
TABLE 22 REAL-WORLD EVIDENCE MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2016–2023 (USD MILLION) 66
TABLE 23 REAL-WORLD EVIDENCE MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2016–2023 (USD MILLION) 67
TABLE 24 REAL-WORLD EVIDENCE MARKET FOR HEALTHCARE PROVIDERS,
BY COUNTRY, 2016–2023 (USD MILLION) 68
TABLE 25 REAL-WORLD EVIDENCE MARKET FOR OTHER END USERS, BY COUNTRY,
2016–2023 (USD MILLION) 69
TABLE 26 REAL-WORLD EVIDENCE MARKET, BY REGION, 2016–2023 (USD MILLION) 72
TABLE 27 NORTH AMERICA: REAL-WORLD EVIDENCE MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 74
TABLE 28 NORTH AMERICA: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 74
TABLE 29 NORTH AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 74
TABLE 30 NORTH AMERICA: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA, 2016–2023 (USD MILLION) 75
TABLE 31 NORTH AMERICA: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 75
TABLE 32 US: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 76
TABLE 33 US: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 77
TABLE 34 US: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 77
TABLE 35 US: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016–2023 (USD MILLION) 78
TABLE 36 CANADA: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 79
TABLE 37 CANADA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 80
TABLE 38 CANADA: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 80
TABLE 39 CANADA: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 81
TABLE 40 EUROPE: REAL-WORLD EVIDENCE MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 83
TABLE 41 EUROPE: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 83
TABLE 42 EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 84
TABLE 43 EUROPE: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 84
TABLE 44 EUROPE: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 85
TABLE 45 GERMANY: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 86
TABLE 46 GERMANY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 86
TABLE 47 GERMANY: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 87
TABLE 48 GERMANY: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 87
TABLE 49 UK: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 88
TABLE 50 UK: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 88
TABLE 51 UK: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 89
TABLE 52 UK: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016–2023 (USD MILLION) 89
TABLE 53 FRANCE: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 90
TABLE 54 FRANCE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 90
TABLE 55 FRANCE: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 91
TABLE 56 FRANCE: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 91
TABLE 57 ITALY: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 92
TABLE 58 ITALY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 93
TABLE 59 ITALY: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 93
TABLE 60 ITALY: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 94
TABLE 61 SPAIN: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 95
TABLE 62 SPAIN: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 95
TABLE 63 SPAIN: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 96
TABLE 64 SPAIN: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 96
TABLE 65 ROE: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 97
TABLE 66 ROE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 97
TABLE 67 ROE: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 98
TABLE 68 ROE: REAL-WORLD EVIDENCE MARKET, BY END USER, 2016–2023 (USD MILLION) 98
TABLE 69 ASIA PACIFIC: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 99
TABLE 70 ASIA PACIFIC: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 99
TABLE 71 ASIA PACIFIC: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 100
TABLE 72 ASIA PACIFIC: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 100
TABLE 73 JAPAN: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 101
TABLE 74 JAPAN: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 101
TABLE 75 JAPAN: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 102
TABLE 76 JAPAN: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 102
TABLE 77 CHINA: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 104
TABLE 78 CHINA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 104
TABLE 79 CHINA: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 105
TABLE 80 CHINA: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 105
TABLE 81 ROAPAC: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 106
TABLE 82 ROAPAC: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 107
TABLE 83 ROAPAC: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 107
TABLE 84 ROAPAC: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 108
TABLE 85 ROW: REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2016–2023 (USD MILLION) 109
TABLE 86 ROW: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE,
2016–2023 (USD MILLION) 109
TABLE 87 ROW: REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2016–2023 (USD MILLION) 109
TABLE 88 ROW: REAL-WORLD EVIDENCE MARKET, BY END USER,
2016–2023 (USD MILLION) 110
TABLE 89 GROWTH STRATEGY MATRIX (2014–2018) 112
TABLE 90 ACQUISITIONS, 2014–2018 112
TABLE 91 PARTNERSHIPS, AGREEMENTS, ALLIANCES, AND COLLABORATIONS, 2014–2017 113
TABLE 92 SERVICE LAUNCHES, 2014–2017 114


LIST OF FIGURES

FIGURE 1 REAL-WORLD EVIDENCE MARKET SEGMENTATION 17
FIGURE 2 RESEARCH DESIGN 21
FIGURE 3 DATA TRIANGULATION METHODOLOGY 26
FIGURE 4 REAL-WORLD EVIDENCE MARKET, BY COMPONENT,
2018 VS. 2023 (USD MILLION) 28
FIGURE 5 REAL-WORLD EVIDENCE MARKET, BY THERAPEUTIC AREA,
2018 VS. 2023 (USD MILLION) 29
FIGURE 6 REAL-WORLD EVIDENCE MARKET, BY END USER, 2018 VS. 2023 (USD MILLION) 29
FIGURE 7 GEOGRAPHIC SNAPSHOT OF THE REAL-WORLD EVIDENCE MARKET 30
FIGURE 8 REAL-WORLD EVIDENCE MARKET IS PROJECTED TO WITNESS A DOUBLE-DIGIT GROWTH IN THE FORECAST PERIOD 31
FIGURE 9 ONCOLOGY SEGMENT COMMANDED THE LARGEST SHARE OF THE
MARKET IN 2017 32
FIGURE 10 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE REAL-WORLD EVIDENCE MARKET IN 2017 33
FIGURE 11 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 34
FIGURE 12 REAL-WORLD EVIDENCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 35
FIGURE 13 GROWTH IN GERIATRIC POPULATION, BY REGION (2015–2050) 36
FIGURE 14 UTILIZATION OF WEARABLES IN CLINICAL TRIALS, BY THERAPEUTIC AREA (2016) 41
FIGURE 15 DATA SETS TO FORM THE LARGEST COMPONENT SEGMENT IN THE REAL-WORLD EVIDENCE MARKET DURING THE FORECAST PERIOD 46
FIGURE 16 EHR ADOPTION BY OFFICE-BASED PHYSICIANS, US (2006–2015) 49
FIGURE 17 E-PRESCRIBING UTILIZATION AMONG PHARMACIES AND PRESCRIBERS
IN THE US (2013–2017) 51
FIGURE 18 INCREASE IN CLINICAL TRIALS DURING 2010–2017, BY THERAPEUTIC AREA 56
FIGURE 19 ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE THE REAL-WORLD EVIDENCE MARKET BY 2023 56
FIGURE 20 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES TO CONTINUE TO DOMINATE THE REAL-WORLD EVIDENCE MARKET IN 2023 64
FIGURE 21 FDA PHASE TRANSITION SUCCESS RATES, 2006–2015 65
FIGURE 22 REAL-WORLD EVIDENCE MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 71
FIGURE 23 NORTH AMERICA: REAL-WORLD EVIDENCE MARKET SNAPSHOT 73
FIGURE 24 CLINICAL TRIALS IN CANADA (2013–2017) 79
FIGURE 25 EUROPE: REAL-WORLD EVIDENCE MARKET SNAPSHOT 82
FIGURE 26 ADULT WEARABLE DEVICE USER BASE AND INTERNET PENETRATION
IN CHINA (2015–2019) 103
FIGURE 27 NUMBER OF OBSERVATIONAL STUDIES IN CHINA, 2013–2017 104
FIGURE 28 KEY DEVELOPMENTS IN THE REAL-WORLD EVIDENCE MARKET
BETWEEN 2014 AND 2018 111
FIGURE 29 IQVIA: COMPANY SNAPSHOT (2017) 115
FIGURE 30 IBM CORPORATION: COMPANY SNAPSHOT (2017) 119
FIGURE 31 PAREXEL: COMPANY SNAPSHOT (2017) 125
FIGURE 32 OPTUM: COMPANY SNAPSHOT (2017) 128
FIGURE 33 PERKINELMER: COMPANY SNAPSHOT (2017) 132
FIGURE 34 ICON PLC: COMPANY SNAPSHOT (2017) 134
FIGURE 35 ORACLE: COMPANY SNAPSHOT (2017) 137
FIGURE 36 COGNIZANT: COMPANY SNAPSHOT (2017) 139
FIGURE 37 SYNEOS HEALTH: COMPANY SNAPSHOT (2017) 141
FIGURE 38 ANTHEM, INC.: COMPANY SNAPSHOT (2017) 143
FIGURE 39 CLINIGEN: COMPANY SNAPSHOT (2017) 146
FIGURE 40 SAS INSTITUTE: COMPANY SNAPSHOT (2017) 148


★調査レポート[リアルワールドエビデンスソリューションの世界市場予測(~2023年)] ( Real World Evidence Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) - Global Forecast to 2023 / HIT6444) 販売に関する免責事項
[リアルワールドエビデンスソリューションの世界市場予測(~2023年)] ( Real World Evidence Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) - Global Forecast to 2023 / HIT6444) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆